Brief: Sarepta Therapeutics Announces Commercial Launch Of Elevidys In Japan
24/02/2026 14:10
Sarepta Therapeutics Inc SRPT.O: SAREPTA THERAPEUTICS ANNOUNCES COMMERCIAL LAUNCH OF ELEVIDYS IN JAPAN SAREPTA THERAPEUTICS INC: COMPANY IS ELIGIBLE TO RECEIVE A $40 MILLION MILESTONE PAYMENT UPON FIRST COMMERCIAL SALE IN JAPAN SAREPTA THERAPEUTICS INC - ELEVIDYS AVAILABLE FOR DUCHENNE PATIENTS AGED 3 TO 8 IN JAPAN SAREPTA THERAPEUTICS INC: COMMERCIAL LAUNCH OF ELEVIDYS IN JAPAN BY CHUGAI PHARMACEUTICAL CO., LTD. Source text: ID:nBw9whgx8a Further company coverage: SRPT.O
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)